https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/interviews

The Latest

TracySwann-1000x667 ITPC

“This Information Will Be Useful in the Future”: How a Tuberculosis Toolkit Became a COVID-19 Timeline

A newly launched chronology traces the unfolding pandemic and the consequences of economic and political decisions around the world.

By Terri Wilder, M.S.W.
liver

Hepatitis D Infection Poses Greater Risks to People Living With HIV, Study Finds

New research suggests a high prevalence of hepatitis D, the most severe form of viral hepatitis, in PLWH in regions of Europe, and a particularly high risk for people who inject drugs.

By Terri Wilder, M.S.W.
prescription telemedicine

Can a Low-Contact, Minimal Monitoring Approach Become the New Normal for Treating Hepatitis C?

No baseline genotyping. Fewer in-person medical visits and lab tests. No need for refills. Could the future of HCV treatment take place almost entirely remotely?

By Terri Wilder, M.S.W.
pain

How Can We Manage Pain Better in Older Adults Living With HIV?

“Telling them now that ‘the government is saying I need to decrease your opioids. ... Sorry you’re going to suffer,’ was just not satisfying to me as a physician,” says Maile Young Karris, M.D.

By Terri Wilder, M.S.W.
Biden Harris

Will the Biden-Harris Administration Breathe Life Back Into Vital HIV and Hepatitis Programs?

We spoke with Amy Killelea at NASTAD, a major national health policy advocacy organization, about the priorities she sees in January 2021 and beyond.

By Terri Wilder, M.S.W.
birds on soil

Histoplasmosis and HIV in the U.S.: Often Forgotten, Never Gone

IDWeek 2020 provided a perfect opportunity to better understand the modern-day impact of histoplasmosis among Americans living with HIV—and to bone up on the basics.

By Terri Wilder, M.S.W.
HIV and COVID-19-iStock-1216628411

HIV Clinicians Have Played a Key Role in U.S. COVID-19 Treatment Guidelines. We Spoke With One of Them.

COVID-19 Treatment Guidelines Panel member Arthur Kim, M.D., discusses the guidelines and the experience of treating COVID-19 from an HIV care provider’s perspective.

By Terri Wilder, M.S.W.
intimate

Understanding U=U Can Improve Health Outcomes for People Living with HIV—but the Message Matters

W. David Hardy, M.D., discusses the takeaway messages for HIV care providers after a recent research paper found that a third of all people living with HIV reported never discussing U=U with their provider.

By Terri Wilder, M.S.W.
smoking

Smoking Rates Are Higher in the LGBTQ Community; Can More Inclusive Data Help?

Scout, Ph.D., the head of the National LGBT Cancer Network, lays out the current state of the interplay between nicotine, cancer, HIV, and people who are LGBTQ.

By Terri Wilder, M.S.W.
monoclonal antibodies

Are Monoclonal Antibodies the Future of COVID-19 Treatment?

Infectious-diseases researcher David Wohl, M.D., talks about a major COVID-19 treatment trial in the works—and how it relates to our efforts against HIV.

By Terri Wilder, M.S.W.